tiprankstipranks
Beam Therapeutics (BEAM)
NASDAQ:BEAM
US Market
BEAM
Beam Therapeutics
RESEARCH TOOLSreports
Want to see BEAM full AI Analyst Report?

Beam Therapeutics (BEAM) Stock Forecast & Price Target

2,235 Followers
See the Price Targets and Ratings of:

BEAM Analyst Ratings

Strong Buy
12Ratings
Strong Buy
11 Buy
1 Hold
0 Sell
Based on 12 analysts giving stock ratings to
Beam
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

BEAM Stock 12 Month Forecast

Average Price Target

$49.91
▲(59.00% Upside)
Based on 12 Wall Street analysts offering 12 month price targets for Beam Therapeutics in the last 3 months. The average price target is $49.91 with a high forecast of $80.00 and a low forecast of $26.00. The average price target represents a 59.00% change from the last price of $31.39.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"15":"$15","48":"$48","81":"$81","31.5":"$31.5","64.5":"$64.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":80,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$80.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":49.90909090909091,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$49.91</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":26,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$26.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[15,31.5,48,64.5,81],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2025","6":"Nov<br/>2025","9":"Feb<br/>2026","12":"May<br/>2026","25":"May<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,30.7,34.49230769230769,38.284615384615385,42.07692307692308,45.86923076923077,49.661538461538456,53.45384615384616,57.246153846153845,61.03846153846153,64.83076923076923,68.62307692307692,72.41538461538461,76.20769230769231,{"y":80,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,30.7,32.17762237762238,33.65524475524475,35.13286713286713,36.61048951048951,38.08811188811189,39.565734265734264,41.043356643356645,42.52097902097902,43.998601398601394,45.476223776223776,46.95384615384616,48.431468531468525,{"y":49.90909090909091,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,30.7,30.338461538461537,29.976923076923075,29.615384615384613,29.253846153846155,28.892307692307693,28.53076923076923,28.16923076923077,27.807692307692307,27.446153846153845,27.084615384615383,26.723076923076924,26.361538461538462,{"y":26,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":19.83,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.19,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.53,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.83,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.31,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.13,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.01,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.05,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.72,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.92,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.69,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.22,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.7,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$80.00Average Price Target$49.91Lowest Price Target$26.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on BEAM
Patrick Trucchio
H.C. Wainwright
H.C. Wainwright
$80
Buy
154.86%
Upside
Reiterated
05/14/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Bernstein Analyst forecast on BEAM
William Pickering
Bernstein
Bernstein
$40→$39
Buy
24.24%
Upside
Assigned
05/13/26
Beam Therapeutics price target lowered to $39 from $40 at BernsteinBeam Therapeutics price target lowered to $39 from $40 at Bernstein
Citi Analyst forecast on BEAM
Samantha Semenkow
Citi
Citi
$68
Buy
116.63%
Upside
Reiterated
05/13/26
Beam Therapeutics: Buy Rating Reaffirmed as Clinical Momentum Builds and $68 Price Target Remains Unchanged
Bank of America Securities Analyst forecast on BEAM
Alec Stranahan
Bank of America Securities
Bank of America Securities
$47
Buy
49.73%
Upside
Reiterated
05/12/26
Analysts Conflicted on These Healthcare Names: Omnicell (NASDAQ: OMCL), Beam Therapeutics (NASDAQ: BEAM) and Zentalis Pharmaceuticals (NASDAQ: ZNTL)
Evercore ISI Analyst forecast on BEAM
Cory Kasimov
Evercore ISI
Evercore ISI
$35→$45
Buy
43.36%
Upside
Reiterated
05/08/26
Evercore ISI Sticks to Their Buy Rating for Beam Therapeutics (BEAM)
Wedbush Analyst forecast on BEAM
David Nierengarten
Wedbush
Wedbush
$65
Buy
107.07%
Upside
Reiterated
05/08/26
Analysts Are Bullish on Top Healthcare Stocks: Celldex (CLDX), Owlet (OWLT)
Canaccord Genuity Analyst forecast on BEAM
Whitney Ijem
Canaccord Genuity
Canaccord Genuity
$75
Buy
138.93%
Upside
Reiterated
05/08/26
Analyst Maintains Buy on Beam Therapeutics, Reiterates $75 Price Target Amid Pipeline Progress and De-Risking Milestones
RBC Capital Analyst forecast on BEAM
Luca Issi
RBC Capital
RBC Capital
$26
Hold
-17.17%
Downside
Reiterated
05/08/26
Analysts Conflicted on These Healthcare Names: Monte Rosa Therapeutics (NASDAQ: GLUE) and Beam Therapeutics (NASDAQ: BEAM)
William Blair Analyst forecast on BEAM
Sami Corwin
William Blair
William Blair
$32
Buy
1.94%
Upside
Reiterated
05/07/26
Analysts' Top Healthcare Picks: Bioventus (BVS), Insmed (INSM)
JonesTrading Analyst forecast on BEAM
Boris Peaker
JonesTrading
JonesTrading
$35
Buy
11.50%
Upside
Reiterated
05/07/26
Analysts Offer Insights on Healthcare Companies: Entrada Therapeutics Inc (NASDAQ: TRDA) and Beam Therapeutics (NASDAQ: BEAM)
Clear Street Analyst forecast on BEAM
William Maughan
Clear Street
Clear Street
$37
Buy
17.87%
Upside
Reiterated
03/25/26
Clear Street sees buying opportunity for Beam Therapeutics after study updateClear Street sees buying opportunity for Beam Therapeutics after study update
J.P. Morgan Analyst forecast on BEAM
Brian Cheng
J.P. Morgan
J.P. Morgan
―
Buy
―
Reiterated
03/25/26
Analysts Offer Insights on Healthcare Companies: Beam Therapeutics (NASDAQ: BEAM), Maze Therapeutics, Inc. (NASDAQ: MAZE) and Daiichi Sankyo Company (Other OTC: DSKYF)
UBS Analyst forecast on BEAM
Michael Yee
UBS
UBS
$28
Hold
-10.80%
Downside
Initiated
01/06/26
Beam Therapeutics initiated with a Neutral at UBSBeam Therapeutics initiated with a Neutral at UBS
Wells Fargo Analyst forecast on BEAM
Yanan Zhu
Wells Fargo
Wells Fargo
$100→$70
Buy
123.00%
Upside
Reiterated
01/05/26
Wells Fargo Reaffirms Their Buy Rating on Beam Therapeutics (BEAM)
Barclays Analyst forecast on BEAM
Gena Wang
Barclays
Barclays
$21
Hold
-33.10%
Downside
Reiterated
11/05/25
Barclays Keeps Their Hold Rating on Beam Therapeutics (BEAM)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on BEAM
Patrick Trucchio
H.C. Wainwright
H.C. Wainwright
$80
Buy
154.86%
Upside
Reiterated
05/14/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Bernstein Analyst forecast on BEAM
William Pickering
Bernstein
Bernstein
$40→$39
Buy
24.24%
Upside
Assigned
05/13/26
Beam Therapeutics price target lowered to $39 from $40 at BernsteinBeam Therapeutics price target lowered to $39 from $40 at Bernstein
Citi Analyst forecast on BEAM
Samantha Semenkow
Citi
Citi
$68
Buy
116.63%
Upside
Reiterated
05/13/26
Beam Therapeutics: Buy Rating Reaffirmed as Clinical Momentum Builds and $68 Price Target Remains Unchanged
Bank of America Securities Analyst forecast on BEAM
Alec Stranahan
Bank of America Securities
Bank of America Securities
$47
Buy
49.73%
Upside
Reiterated
05/12/26
Analysts Conflicted on These Healthcare Names: Omnicell (NASDAQ: OMCL), Beam Therapeutics (NASDAQ: BEAM) and Zentalis Pharmaceuticals (NASDAQ: ZNTL)
Evercore ISI Analyst forecast on BEAM
Cory Kasimov
Evercore ISI
Evercore ISI
$35→$45
Buy
43.36%
Upside
Reiterated
05/08/26
Evercore ISI Sticks to Their Buy Rating for Beam Therapeutics (BEAM)
Wedbush Analyst forecast on BEAM
David Nierengarten
Wedbush
Wedbush
$65
Buy
107.07%
Upside
Reiterated
05/08/26
Analysts Are Bullish on Top Healthcare Stocks: Celldex (CLDX), Owlet (OWLT)
Canaccord Genuity Analyst forecast on BEAM
Whitney Ijem
Canaccord Genuity
Canaccord Genuity
$75
Buy
138.93%
Upside
Reiterated
05/08/26
Analyst Maintains Buy on Beam Therapeutics, Reiterates $75 Price Target Amid Pipeline Progress and De-Risking Milestones
RBC Capital Analyst forecast on BEAM
Luca Issi
RBC Capital
RBC Capital
$26
Hold
-17.17%
Downside
Reiterated
05/08/26
Analysts Conflicted on These Healthcare Names: Monte Rosa Therapeutics (NASDAQ: GLUE) and Beam Therapeutics (NASDAQ: BEAM)
William Blair Analyst forecast on BEAM
Sami Corwin
William Blair
William Blair
$32
Buy
1.94%
Upside
Reiterated
05/07/26
Analysts' Top Healthcare Picks: Bioventus (BVS), Insmed (INSM)
JonesTrading Analyst forecast on BEAM
Boris Peaker
JonesTrading
JonesTrading
$35
Buy
11.50%
Upside
Reiterated
05/07/26
Analysts Offer Insights on Healthcare Companies: Entrada Therapeutics Inc (NASDAQ: TRDA) and Beam Therapeutics (NASDAQ: BEAM)
Clear Street Analyst forecast on BEAM
William Maughan
Clear Street
Clear Street
$37
Buy
17.87%
Upside
Reiterated
03/25/26
Clear Street sees buying opportunity for Beam Therapeutics after study updateClear Street sees buying opportunity for Beam Therapeutics after study update
J.P. Morgan Analyst forecast on BEAM
Brian Cheng
J.P. Morgan
J.P. Morgan
―
Buy
―
Reiterated
03/25/26
Analysts Offer Insights on Healthcare Companies: Beam Therapeutics (NASDAQ: BEAM), Maze Therapeutics, Inc. (NASDAQ: MAZE) and Daiichi Sankyo Company (Other OTC: DSKYF)
UBS Analyst forecast on BEAM
Michael Yee
UBS
UBS
$28
Hold
-10.80%
Downside
Initiated
01/06/26
Beam Therapeutics initiated with a Neutral at UBSBeam Therapeutics initiated with a Neutral at UBS
Wells Fargo Analyst forecast on BEAM
Yanan Zhu
Wells Fargo
Wells Fargo
$100→$70
Buy
123.00%
Upside
Reiterated
01/05/26
Wells Fargo Reaffirms Their Buy Rating on Beam Therapeutics (BEAM)
Barclays Analyst forecast on BEAM
Gena Wang
Barclays
Barclays
$21
Hold
-33.10%
Downside
Reiterated
11/05/25
Barclays Keeps Their Hold Rating on Beam Therapeutics (BEAM)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
xxx
xxx
xxx
xxx
xxx
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Beam Therapeutics

3 Months
xxx
Success Rate
14/18 ratings generated profit
78%
Average Return
+4.78%
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 3 Months would result in 77.78% of your transactions generating a profit, with an average return of +4.78% per trade.
1 Year
Alec StranahanBank of America Securities
Success Rate
9/11 ratings generated profit
82%
Average Return
+39.91%
Copying Alec Stranahan's trades and holding each position for 1 Year would result in 81.82% of your transactions generating a profit, with an average return of +39.91% per trade.
2 Years
xxx
Success Rate
17/18 ratings generated profit
94%
Average Return
+38.89%
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 2 Years would result in 94.44% of your transactions generating a profit, with an average return of +38.89% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

BEAM Analyst Recommendation Trends

Rating
Jan 26
Feb 26
Mar 26
Apr 26
May 26
Strong Buy
12
11
18
17
17
Buy
17
20
19
11
10
Hold
3
2
2
1
1
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
32
33
39
29
28
In the current month, BEAM has received 27 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. BEAM average Analyst price target in the past 3 months is 49.91.
Each month's total comprises the sum of three months' worth of ratings.

BEAM Financial Forecast

BEAM Earnings Forecast

Next quarter’s earnings estimate for BEAM is -$1.11 with a range of -$1.24 to -$0.95. The previous quarter’s EPS was -$0.91. BEAM beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year BEAM has Performed in-line its overall industry.
Next quarter’s earnings estimate for BEAM is -$1.11 with a range of -$1.24 to -$0.95. The previous quarter’s EPS was -$0.91. BEAM beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year BEAM has Performed in-line its overall industry.

BEAM Sales Forecast

Next quarter’s sales forecast for BEAM is $14.53M with a range of $0.00 to $33.30M. The previous quarter’s sales results were $31.74M. BEAM beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year BEAM has Performed in-line its overall industry.
Next quarter’s sales forecast for BEAM is $14.53M with a range of $0.00 to $33.30M. The previous quarter’s sales results were $31.74M. BEAM beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year BEAM has Performed in-line its overall industry.

BEAM Stock Forecast FAQ

What is BEAM’s average 12-month price target, according to analysts?
Based on analyst ratings, Beam Therapeutics’s 12-month average price target is 49.91.
    What is BEAM’s upside potential, based on the analysts’ average price target?
    Beam Therapeutics has 59.00% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is BEAM a Buy, Sell or Hold?
          Beam Therapeutics has a consensus rating of Strong Buy which is based on 11 buy ratings, 1 hold ratings and 0 sell ratings.
            What is Beam Therapeutics’s price target?
            The average price target for Beam Therapeutics is 49.91. This is based on 12 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $80.00 ,the lowest forecast is $26.00. The average price target represents 59.00% Increase from the current price of $31.39.
              What do analysts say about Beam Therapeutics?
              Beam Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 12 Wall Streets Analysts.
                How can I buy shares of BEAM?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.